January 21, 2022
Article
The highly transmissible and dominant Omicron variant of COVID-19 places added pressure on infection preventionists and other clinicians to determine just what they’re dealing with.
December 23, 2021
Article
In the space of 2 days, the FDA approved at-home oral treatments for patients with mild-to-moderate COVID-19, drug that were months in development. Today, it was Merck and Ridgeback Biotherapeutics’ turn.
October 25, 2021
Article
Moderna’s phase 2/3 pediatric trial showed a lesser dose of the company’s 2-dose COVID-19 vaccine mRNA-1273 is associated with a significant neutralizing antibody response in children aged 6 to
September 21, 2021
Article
Investigators concluded that their data demonstrate the “high and stable effectiveness” of the single-dose COVID-19 vaccine across both high-risk patient subpopulations, as well as residents in areas more adversely affected by the delta variant.
August 23, 2021
Article
Health care experts hope that the move will induce the vaccine hesitant—in the public, and among health care professionals—to get inoculated in the hope that that will stem the rising tide of the delta variant.
August 12, 2021
Article
The findings provide support for 2-dose vaccine uptake in the wake of surging cases driven by the highly transmissible delta variant.